Efficacy of Cefixime in Respiratory Tract Infections

Document Type


Publication Date



Cefixime, the first orally-administered third-generation cephalosporin, has a broad spectrum of antibacterial activity. Cefixime is active against a wide range of gram-positive and gram-negative organisms, including common upper and lower respiratory tract pathogens such as Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Moraxella (Branhamella) catarrhalis, and Klebsiella species, but excluding Staphylococcus aureus. Cefixime exhibits enhanced resistance to hydrolysis by beta lactamases, and should prove a useful agent in clinical settings where established or emerging resistance is likely. Cefixime is formulated for once-daily dosage, a factor that should enhance patient compliance.

This document is currently not available here.